The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …

Effective therapeutics have been developed against acute Ebola virus disease (EVD) in both
humans and experimentally infected nonhuman primates. However, the risk of viral …

Ebola virus (EBOV), member of genus Ebolavirus, family Filoviridae, have a non-segmented,
single-stranded RNA that contains seven genes:(a) nucleoprotein (NP),(b) viral protein 35 …

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear
Defense (JPEO-CBRND) began development of a broad-spectrum antiviral countermeasure …

Background Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a
respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) …

Ebolaviruses cause a severe and often fatal illness with the potential for global spread.
Monoclonal antibody-based treatments that have become available recently have a narrow …

Infections with rabies virus (RABV) and related lyssaviruses are uniformly fatal once virus
accesses the central nervous system (CNS) and causes disease signs. Current …

The Ebola virus (EBOV) is still highly infectious and causes severe hemorrhagic fevers in
primates. However, there are no regulatorily approved drugs against the Ebola virus disease …